HONG KONG, Nov. 1, 2023 /PRNewswire/ — Recently, one of the most significant events of the global communication year — Network X 2023 was held in Paris Expo Porte de Versailles, attracted more than 3,000 attendees from 88 countries. As an important sponsor and exhibitor this year, China Telecom Global Limited ("China Telecom Global") debuted on the international stage with three major achievements. During the event, leaders from the World Broadband Association (WBBA) and China Telecom Global shared hot topics such as broadband network, infrastructure, cutting-edge technology and digital transformation.

In this exhibition, China Telecom Global took "Empowering a Shared Digital Future" as the theme. Through 3D interactive demonstration, large screen exhibition and other immersive forms, three major capabilities of China Telecom were unveiled, which included Global Infrastructure, Cloud Network Broadband and eSurfing Cloud. During the three days, many visitors from worldwide shuttled around the booth. Via the explanation provided by the presenter, a deeper understanding of China Telecom’s overall strength and solution capabilities was achieved, laying a solid foundation for further collaboration in the future.

WBBA Broadband Development Conference 2023 was held on the first day of Network X. WBBA’s first Board Chairman, former General Manager of China Telecom Li Zhengmao, and Vice President of China Telecommunications Corporation Li Jun made key speeches respectively.

Chairman Li Zhengmao emphasized that the primary objective of WBBA is to foster win-win cooperation, drive innovative development, and bridge the digital divide. Let us work together to achieve the sustainable development goals proposed by the United Nations and the International Telecommunication Union, fully leverage the important role of cloud broadband, and contribute to developing the global digital economy.

Vice President Li Jun highlighted that China Telecom is actively building a new digital information infrastructure, centered around cloud-network integration and characterized by new connectivity, new computility capabilities, new platforms, new security and new sustainability. This robust digital foundation serves as a catalyst for the advancement of new industrialization.

On October 25 and 26, Wu Xiaolei, Executive Vice President of China Telecom Global Limited, along with Charlie Cao from China Telecom Europe Company, presented their remarkable accomplishments and global infrastructure advancements achieved in recent years.

Executive Vice President Wu Xiaolei analyzed the challenges and opportunities faced by telecom operators under the global digital transformation, and shared the digital information infrastructure of China Telecom that spans the world. He stressed that China Telecom will unswervingly implement Cloudification and Digital Transformation Strategy, build a service-oriented, technology-oriented and security-oriented enterprise, and share the achievements of high-quality development with partners and customers around the world.

Charlie Cao highlighted the pivotal role of DICT and cloud technology in modern telecommunications, emphasizing their crucial importance in facilitating digital transformation for enterprises. Charlie Cao stated that China Telecom has always been committed to providing cutting-edge digital solutions for enterprises around the world, and has accumulated a large number of innovative practices and successful cases of overseas cooperation in fields such as data analysis, cloud services, and virtualization technology.

In the future, China Telecom Global will continue to fully leverage its resources and technological advantages, promote the upgrading of its own product capabilities, assist eSurfing Cloud in expanding overseas, and provide new industrial digital solutions, platform capabilities, and product services for domestic and foreign enterprises to expand globally, work together with global partners to create a digital future!

Source : Empowering a Shared Digital Future: China Telecom Global Radiates Brilliance at Network X 2023

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

Company rebrands healthcare business as a strategic enabler

SPARTANBURG, S.C., Nov. 1, 2023 /PRNewswire/ — Today, global diversified manufacturer Milliken & Company unveiled a new brand platform for its healthcare business. OVIK Health, as Milliken Healthcare Products, LLC, will now be known, represents a new chapter for Milliken’s healthcare innovations—one that reflects its unique position in the marketplace and builds momentum for its portfolio of leading solutions the healthcare industry has come to depend on.

Global diversified manufacturer Milliken & Company unveiled a new brand platform for its healthcare business. Milliken Healthcare Products will now be known as OVIK Health,

"Launching OVIK Health marks a new era in our work to positively impact the healthcare industry," shares Halsey Cook, president and CEO of Milliken & Company. "Through OVIK, we reaffirm our commitment to providing innovative healthcare solutions and open the door to future opportunities that can heal, protect and support patients."

The rebranding begins today, with an expected completion date of December 1, 2023. Milliken Healthcare Products will transition to OVIK Health in all brand and visual instances; however, all current healthcare product names will remain the same. OVIK Health, as a subsidiary of Milliken & Company, will carry forward Milliken’s portfolio of wound and burn dressings, compression solutions, cohesive bandages, and tapes.

OVIK Health’s portfolio is defined by Milliken’s chemical and textile expertise and enhanced by Andover Healthcare’s cohesive and compression innovations, when Milliken formally acquired Andover Healthcare in 2019. Some of its most notable offerings include the proprietary Active Fluid Management® technology for wound dressings, the SelectSilver antimicrobial technology, and the EasyTear technology for cohesive and compression products. These offerings, along with Milliken’s entire line of healthcare innovations, will continue to be available under OVIK Health.

"When we entered the healthcare business in 2005 and acquired Andover Healthcare in 2019, we were guided by the desire to help improve patients’ lives globally with a range of superior products that are marked by dependability, ease-of-use, and innovative excellence," adds Shri Parikh, EVP of Milliken and president of OVIK Health. "That commitment does not change with the launch of OVIK Health. It unites us as a team of innovators with a single brand and clear mission of advancing healthcare technologies to improve patient care."

Customers, suppliers and distributors can expect individual communications regarding the rebrand in the coming weeks. To learn more about OVIK Health, visit OVIKhealth.com.

About OVIK Health  
OVIK Health pioneers breakthrough products to help improve patients’ lives—and the lives of those who care for them—around the world. Drawing on a legacy of textile manufacturing and bolstered by the spirit of creating a positive impact that will last generations, OVIK Health envisions a world where technical solutions can redefine patient outcomes for the better. Alongside mainstay medical products like wound and burn dressings, OVIK Health’s portfolio includes compression solutions, cohesive bandages, and tapes that serve the traditional medical fields as well as the animal care and sports medicine markets. Learn more at OVIKhealth.com.

About Milliken  
Milliken & Company is a global manufacturing leader whose focus on materials science delivers tomorrow’s breakthroughs today. From industry-leading molecules to sustainable innovations, Milliken creates products that enhance people’s lives and deliver solutions for its customers and communities. Drawing on thousands of patents and a portfolio with applications across the textile, specialty chemical, flooring and healthcare businesses, the company harnesses a shared sense of integrity and excellence to positively impact the world for generations. Discover more about Milliken’s curious minds and inspired solutions at milliken.com and on Facebook, Instagram, and LinkedIn.

Source : Milliken & Company Launches OVIK Health

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

MIAMI and PALO ALTO, Calif., Nov. 1, 2023 /PRNewswire/ — Foundever™, a global leader in the customer experience (CX) industry, has announced a new strategic partnership with Zenarate, the leading AI Simulation Training solution for customer-facing agents, in which the two organizations seek to leverage state-of-the-art technology to transform employee training within the customer experience industry. This partnership marks a significant milestone for both companies in their commitment to elevate customer service training through cutting-edge solutions. 

"Equipping our people with the best training tools and resources is key to delivering exceptional customer experiences," said Laurent Uberti, president, CEO & founder of Foundever. "Zenarate’s AI-training technology can accelerate our agents’ proficiency in a dynamic and efficient way. I’m excited to begin this partnership which supports our team in preparing for the future and becoming ready to shape it." 

"We are thrilled to partner with Foundever and bring AI Coach to thousands of agents to ensure exceptional customer experiences for global brands," said Brian Tuite, co-founder and CEO of Zenarate. "Helping agents master the skills necessary to solve complex problems and deliver superior empathetic experiences will bolster the value Foundever delivers to brands that strive to improve the ever-important human aspects of outstanding customer experiences."  

By joining forces with Zenarate, Foundever further augments its customer-centric CX training program with state-of-the-art technology, thus revolutionizing the approach to customer service training. This partnership highlights both companies’ forward-thinking approach to employee training and development, focusing on utilizing AI simulation to create an environment conducive to experiential learning. 

Foundever and Zenarate are setting a new standard in customer experience training, significantly propelling proficiency and instilling agents’ confidence before engaging in their first customer conversations, ultimately benefiting customers who will gain an enhanced quality of service.

Learn more about Foundever at www.foundever.com. To learn more about Zenarate’s AI Coach and its potential applications, visit www.zenarate.com.

About Zenarate
Zenarate is a leader in AI Simulation Training focused on developing top-performing contact center agents who consistently deliver a superior customer experience. The Zenarate AI Coach platform is purpose built to develop outstanding customer service and sales agents. It trains, certifies, measures, and coaches millions of agents in over 79 languages worldwide based on our customer’s perfect call outcomes and requirements. Ensuring they’re prepared before they ever go live with customers and continuously developing them once they do. Zenarate has improved agent Speed to Proficiency, First Call Resolution, and Agent Retention for leading enterprises around the world in financial services, healthcare, insurance, telecommunications, technology, retail, and travel industries. For more information, visit www.zenarate.com.   

About Foundever™
Foundever™ is a global leader in the customer experience (CX) industry. With 170,000 associates across the globe, we’re the team behind the best experiences for +750 of the world’s leading and digital-first brands. Our innovative CX solutions, technology and expertise are designed to support operational needs for our clients and deliver a seamless experience to customers in the moments that matter. 

Supporting +9 million customer conversations every day in +60 languages across 45 countries, Foundever combines global strength and scale with the agile, entrepreneurial approach of our founder-led culture, enabling companies of all sizes and industries to transform their CX. 

Get to know us at www.foundever.com and connect with us on LinkedIn, Twitter, Facebook and Instagram. 

Media contacts
Rebecca Sanders
[email protected]

Jacob Harvey
[email protected]

Source : Foundever™ and Zenarate Announce Strategic Partnership to Revolutionize Customer Experience Training

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

HOHHOT, China, Nov. 1, 2023 /PRNewswire/ — On October 30, Yili Group released its financial results for the first three quarters of FY2023. During the reporting period, the company’s revenue amounted to 97.404 billion yuan (approx. USD 13.32 billion) and net profit rose by 16.36%.

Yili reports record high revenue approaching 100 billion yuan in the first three quarters of FY2023

These record high figures indicate a continuous improvement in Yili’s core business capabilities. The Asian dairy giant continued to step up the application of R&D outcomes, evidenced by the launch of a series of innovative healthy products that have received positive feedback from consumers.

In terms of business units, Yili’s liquid milk business secured its leading position in the segment with accelerated growth throughout Q1 to Q3. It reported a revenue of 65.432 billion yuan (approx. USD 8.93 billion) from January to September, a year-on-year increase of 2.07%, and the growth rate reached 8.48% in the strong third quarter. Adult milk powder continued its strong growth, leading the segment with its market share rising to 23.9%. The rapidly growing ice cream business also topped the segment in terms of market share and reported a revenue of 10.383 billion yuan (approx. USD 1.42 billion).

The achievements are attributable to Yili’s strong capabilities in transforming its key innovation outcomes into top-selling new products. Benefiting from its digital-oriented upgrading across the entire value chain, the company has seen significant progress in overall business efficiency which is shaping Yili’s new competitive advantages. While driving robust development in business performance, Yili’s digitalized operation system is also contributing to a sustainable dairy industry, representing success both commercially and socially.

In upstream segments of the industry, Yili has adopted a recycling-oriented sustainability model. It has built a number of ecological smart farms that are equipped with intelligent, low-carbon and eco-friendly facilities. Featuring full-process unmanned operations, the smart farm system pioneers the industry in enhancing efficiency and promoting green and sustainable transformation. The system is also being introduced across China as part of Yili’s efforts to reduce the carbon footprint of the entire dairy industry.

At midstream level, Yili has built five net-zero carbon factories and had 31 factories certified as state-level "green factories". In addition, all of its factories in China have completed digitalized upgrades. Embracing digital empowerment and recycling technology, Yili manages to multiply production efficiency and propel green manufacturing.

Towards the downstream, Yili remains a trendsetter in promoting sustainable consumption by adopting eco-friendly packaging. Its SATINE Environmentally Sustainable Packaging with No Ink or Printing won the IDF Dairy Innovation Award, as a recognition of its innovative solutions for reducing carbon footprint.

The company’s years of efforts in the ESG field have also earned high recognition from the capital market. In the MSCI ESG Ratings 2023, Yili also received Grade A rating, the highest among all A-share listed dairy producers.

Image Attachments Links:

   Link: https://iop.asianetnews.net/view-attachment?attach-id=442984

   Caption: Yili reports record high revenue approaching 100 billion yuan in the first three quarters of FY2023

Source : Yili Reports Record High Revenue Approaching 100 Billion Yuan in the First Three Quarters of FY2023

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

Six posters featuring the Lunit SCOPE suite and new insights into the tumor microenvironment are to be showcased at the SITC 2023 Annual Meeting

SEOUL, South Korea, Nov. 1, 2023 /PRNewswire/ — Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced the presentation of six studies at the upcoming SITC (Society for Immunotherapy of Cancer) 2023 Annual Meeting, taking place from November 1 to 5, in San Diego, California.

Lunit AI-powered TIL analyzer, Lunit SCOPE IO

During this year’s meeting, Lunit plans to highlight the predictive value and analytical power of its Lunit SCOPE suite in various types of cancer, such as non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC).

A collaborative study with the Samsung Medical Center assessed tumor-infiltrating lymphocytes (TILs) using AI-powered spatial analysis with Lunit SCOPE IO in EGFR-mutated non-small cell lung cancer (NSCLC) patients pre- and post-tyrosine kinase inhibitors (TKI) treatment. The study found that EGFR-TKI affects the immune landscape of EGFR-mutated NSCLC as higher PD-L1 expression and differential immune phenotypes. Patients with an inflamed immune phenotype after EGFR-TKI treatment showed a more favorable response to subsequent immune checkpoint inhibitors (ICI) treatment. The study found that inflamed immune phenotype after EGFR-TKI treatment showed a higher overall response (OR; 40.0% vs. 7.5%) and better progression-free survival (PFS; 4.1 vs. 1.4 months) than other immune phenotype groups (excluded and desert type) to ICI treatment.

In another study, Lunit assessed the distribution of TILs in six subtypes of triple-negative breast cancer (TNBC) and their association with driver mutations. By analyzing The Cancer Genome Atlas breast cancer dataset using Lunit SCOPE IO, the study found that the immunomodulatory (IM) subtype of TNBC has a significantly higher mean intratumoral (iTIL), stromal (sTIL), and total TIL (tTIL) score than other TNBC subtypes. Additionally, TNBC samples with PIK3CA mutation/amplification or PTEN loss and BRCA1 or BRCA2 mutation each showed a higher total TIL score than those without mutation. This demonstrates that the TIL distribution can be a valuable biomarker for navigating the optimal treatment strategy in TNBC.

Lunit also explored the correlation between methylation burden and AI-based immune phenotype in The Cancer Genome Atlas (TCGA) Pan-Cancer Atlas dataset, which included 22 tumor types and a total of 6243 samples. The study found that the degree of methylation aberrancy in cancer is linked with TIL infiltration in the tumor microenvironment (TME) assessed by Lunit SCOPE IO.

Another study investigated the effect of tumor fragmentation index (TFI), the number of tumor fragments per total tumor area, in TME. In the study, a total of 7,472 TCGA H&E whole-slide images across 23 cancer types were analyzed with Lunit SCOPE IO. The study found that tumors with high TFI are closely correlated with high fibroblast infiltration but showed low IFNG, IL1A, and IL17A, genes that trigger inflammation as cancer grows.

"We are excited to be back to this year’s SITC with our six groundbreaking studies that demonstrate the potential of our Lunit SCOPE suite in guiding treatment strategies for NSCLC and TNBC. We’ve also found valuable biomarkers and correlations that could lead to predictive information about patients’ immune response and the metastatic potential of the cancer tumor," said Brandon Suh, CEO of Lunit. "Through our participation in the SITC conference, we will continue to back the efficacy of our Lunit SCOPE suite. At the same time, we are committed to seeking collaborations with healthcare giants worldwide to further our mission of advancing tailored cancer treatment."

Visit Lunit’s booth at SITC 2023 at Booth #227 to learn more about these pioneering studies. To schedule a meeting with the Lunit team, please reach out to [email protected].

Lunit’s Abstracts at SITC 2023

No.

Abstract
No. #

Title

Type

1

202

Spatial analysis of tumor-infiltrating lymphocytes in tumor microenvironment in non-small cell lung cancer patients who have resistance after EGFR tyrosine kinase inhibitors 

Poster

2

961

Tumor-infiltrating lymphocytes in tumor microenvironment assessed by artificial intelligence powered H&E image analyzer is correlated with immunomodulatory subtype of triple-negative breast cancer

Poster

3

1446

Pan-cancer methylation analysis reveals a significant correlation of immune-desert phenotype with methylation aberrancy

Poster

4

1293

Fragmented pattern of tumor mass is related to fibroblast activation mitigating spatial interaction between tumor and immune cells

Poster

5

1308

Artificial intelligence (AI)-powered immune phenotyping based on programmed death ligand 1 (PD-L1) immunohistochemistry (IHC) in triple negative breast cancer (TNBC)

Poster

6

614

Safety and efficacy of YBL-006, a novel anti-PD-1 antibody, in advanced solid tumors including G3 NET/NEC: Results from a phase 1/2a study

Poster

About Lunit
Lunit is a deep learning-based medical AI company on a mission to conquer cancer. Our focus is on developing AI solutions for precision diagnostics and therapeutics, ensuring the right diagnosis, and treatment, at the right cost for each patient. Lunit is devoted to developing advanced medical image analytics and AI-based biomarkers via cutting-edge technology.

Founded in 2013, Lunit has been acknowledged around the world for its advanced, state-of-the-art technology and its application in medical images. As a medical AI company grounded on clinical evidence, the company’s findings are presented in major peer-reviewed journals, such as the Journal of Clinical Oncology and JAMA Network Open, and global conferences, including ASCO and AACR.

After receiving FDA clearance and the CE Mark, our flagship Lunit INSIGHT suite is clinically used in approximately 2,000+ hospitals and medical institutions across 40+ countries. Lunit is headquartered in Seoul, South Korea, with offices and representatives worldwide. For more information, please visit lunit.io

About Lunit SCOPE
Lunit SCOPE is a suite of AI-powered software that analyzes tissue slide images for digital pathology and AI biomarker development, aiming to optimize workflow and facilitate more accurate and predictive clinical data for clinicians and researchers.

Lunit SCOPE platform offers multiple AI-powered tissue analysis products and assays that can streamline digital pathology workflow and diagnostics and enhance the drug development process.

Lunit SCOPE IO analyzes the tumor microenvironment (TME) based on H&E analysis and provides AI-based predictive clinical outcome information. In addition, AI-driven Immunohistochemistry (IHC) slide analysis services are offered through products such as Lunit SCOPE PD-L1, Lunit SCOPE HER2, Lunit SCOPE ER/PR, and others.

Source : AI-Powered Tumor Microenvironment Analysis Predicts Treatment Outcomes in NSCLC Patients with EGFR Mutation: Groundbreaking Studies to be Presented by Lunit at SITC 2023

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

Yeh Hong-chieh’s Son Signs Intention for Artifact Donation, Enriching the National Comic Museum

TAIPEI, Nov. 1, 2023 /PRNewswire/ — The 14th GCA Ceremony (Golden Comic Awards) recently concluded at the Taipei New Horizon Building. This edition saw 199 works submitted for the competition, with a total of 24 entries selected as finalists. The GCA Grand Prize was awarded to BliSS for the work "Helena and Mr. Big Bad Wolf (Part 1, Part 2)." Minister of Culture Shih Che presented the Special Contribution Award to comic researcher Teh Ling HUNG and bore witness as Yeh Hong-chieh’s son, Yeh Chia-lung, signed an intention for artifact donation, contributing significant pieces to the upcoming Taichung National Comic Museum’s collection!

Minister of Culture Shih Che taking a photo with the winners of the 14th GCA/Photo: TTV

The GCA Ceremony, a national-level comic award organized by Taiwan’s Ministry of Culture, announced this year’s winners. The Best New Talent and the Cross-media Cooperation awards were presented to Peter Mann for "BLA BLA SONG," and the Best Editor award was awarded to Chu Yen Hung for "Island Rhapsody: Listen to the Voice of Taiwan."

The Comic of the Year award featured six winners: Chang Sheng for "YAN 3," Zuo Hsuan for "The Banana Sprout vol.1," BliSS for "Helena and Mr. Big Bad Wolf (Part 1, Part 2)," Kiya Chang for "Formosa Oolong Tea 5," Ding Pao-Yen for "Console, 2073," and Lin I Chen for "The 207th bone."

In the end, BliSS’s "Helena and Mr. Big Bad Wolf (Part 1, Part 2)" claimed the prestigious GCA Grand Prize for this year. The Ministry of Culture also announced that next year’s GCA Ceremony will be held in Taichung.

The judging panel, when evaluating the Best New Talent award, Best Cross-media Application award, and Best Editor award, was impressed by the maturity of the works, which displayed a remarkable blend of expressiveness and vitality. These works showcased the artists’ creative prowess and the organizational and planning skills of the editors, offering a glimpse into the dynamic nature of comics as a versatile and multifaceted medium in this day and age. In the category of the Comic of the Year award, there was richness in style and diversity, with a communicative power that spans across different age groups. While focusing on history and humanity, these works also tightly grasp current and future issues. This allows readers to gain insight into the perspectives and reflections of contemporary creators.

Recipient of the Special Contribution Award, Teh Ling Hung, has dedicated over 40 years to researching Taiwan’s comic history. He has amassed an extensive collection and conducted research on the development of Taiwanese comics from the Japanese colonial era to contemporary times. He has published numerous works, engaged actively in international seminars, and yet, he remains humble about his contributions, stating, "All I’ve been doing is writing diligently, to let people around the world see that Taiwanese comics deserve a place on the global map."

During the ceremony, there was also a significant event where the son of the renowned comic artist Yeh Hong-chieh, Mr. Yeh Chia-lung, signed an intention letter for the donation of artifacts. This action demonstrates his support for the upcoming National Comic Museum. Mr. Yeh Chia-lung believes that his father’s creation, " Zhuge Si Lang," has had a profound impact on an entire generation’s childhood. It represents the popular culture, history, and the shared memories of all Taiwanese people at that time. He stated, "’Zhuge Si Lang’ represents a public good of our society."

The Ministry of Culture has announced that, in line with the forthcoming opening of the National Comic Museum at the end of the year, the GCA and related activities will be relocated to the National Comic Museum. Furthermore, they have extended invitations to international curators from comic museums or festivals to engage in discussions with local comic artists and industry representatives.

Source : The 14th GCA Ceremony Conclude Successfully

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

SHENZHEN, China, Nov. 1, 2023 /PRNewswire/ — SIBIONICS, the world’s third-largest Continuous Glucose Monitoring System (CGM) brand, is delighted to announce that it has received the CE Mark for its revolutionary GS1 CGM. This significant milestone marks a momentous achievement for SIBIONICS, facilitating the distribution and utilization of this game-changing technology throughout the European market.

The CE Mark, also known as the "Conformité Européene" or European Conformity, is a certification that confirms a product’s compliance with European Union (EU) health and safety standards, serving as proof of the products’ quality, safety, and efficacy.

Founded in 2015, SIBIONICS boasts a workforce exceeding 700 individuals, with over 40% actively engaged in research and development efforts. To date, SIBIONICS has collaborated with 1,600 hospitals on integrating the GS1 CGM for inpatient treatment, benefiting over 600,000 users worldwide in managing their diabetes. With an annual production capacity of 6,000,000 units and consistently achieving a low MARD value of 8.83% in each batch, SIBIONICS is well-equipped to serve a larger customer base.

At its core, the SIBIONICS GS1 CGM System is designed to empower both healthcare professionals and patients with the information needed to make informed treatment decisions and maintain optimal glucose control.

The SIBIONICS GS1 CGM offers users 14 days of calibration-free continuous glucose monitoring solution, empowering them with the capability to transmit glucose data to their monitoring devices or mobile applications and generate professional AGP reports. To assist users in better diabetes management, the GS1 CGM also facilitates data sharing with friends and family while seamlessly integrates the latest ProView remote access platform. This equips healthcare providers with the ability to monitor remotely and deliver timely medical interventions as needed.

As an innovative MedTech company that combines medical technology with artificial intelligence, SIBIONICS is committed to extending their innovative and groundbreaking diabetes management technology and expertise to more diabetes patients worldwide.

Simultaneously, SIBIONICS is vigorously expanding its presence in various specialized segments within the area of health management. Their successful launch of the consumer-grade biowearable – the KS1 Continuous Ketone Monitoring System(CKM), has garnered enthusiastic acclaim from consumers.

Starting today, SIBIONICS GS1 CGM products will gradually become available for pre-sales in EU countries, the UK, and other European countries. Those interested can find more information on official website at www.sibionicscgm.com.

Contact
Sandra Zhang
zy.zhang@sibionics.com

Source : SIBIONICS Achieves Milestone: Receiving CE Mark for Its Groundbreaking GS1 Continuous Glucose Monitoring System

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network